CA2020199A1 - Uses of sulphated sugars - Google Patents

Uses of sulphated sugars

Info

Publication number
CA2020199A1
CA2020199A1 CA 2020199 CA2020199A CA2020199A1 CA 2020199 A1 CA2020199 A1 CA 2020199A1 CA 2020199 CA2020199 CA 2020199 CA 2020199 A CA2020199 A CA 2020199A CA 2020199 A1 CA2020199 A1 CA 2020199A1
Authority
CA
Canada
Prior art keywords
skin
treatment
prophylaxis
medicament
connective tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2020199
Other languages
French (fr)
Other versions
CA2020199C (en
Inventor
Daniel Bar-Shalom
Niels Bukh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buhk Meditec AS
Original Assignee
Buhk Meditec AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buhk Meditec AS filed Critical Buhk Meditec AS
Priority to CA 2020199 priority Critical patent/CA2020199C/en
Publication of CA2020199A1 publication Critical patent/CA2020199A1/en
Application granted granted Critical
Publication of CA2020199C publication Critical patent/CA2020199C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Use of a sulphated mono- or disaccharide or a salt or complex thereof for the preparation of a medicament for topical application to the skin or to any non-gastrointestinal, non-oral mucosal surface of an animal or a human, including the lining of body cavities, for the prophylaxis or treatment of any manifestation of inflammation or infection, for modification or facilitation of tissue regenerative processes, for the modulation of immune reactions, for the treatment or prophylaxis of non-bladder pre-malignant or malignant disorders, or for the prophylaxis or treatment of irritation, burns, or ulcera-tion of the skin, connective tissue, or non-gastrointestinal, non-oral mucosa; or for the preparation of a medicament for topical application to the skin or any non-oral mucosal surface of an animal or a human for the treatment of laceration, lesions, or surgical wounds of the skin, connective tissue, or non-oral mucosa, or for the prophylaxis or treatment of aging of skin, connective tissue, or non-oral mucosa. The medicament may be in the form of a powder, paste, ointment, lotion, gel, cream, salve, emulsion, suspension, solution, spray, sponge, strip, plaster, pad, dressing, or ostomy plate.
CA 2020199 1990-06-29 1990-06-29 Uses of sulphated sugars Expired - Fee Related CA2020199C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2020199 CA2020199C (en) 1990-06-29 1990-06-29 Uses of sulphated sugars

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2020199 CA2020199C (en) 1990-06-29 1990-06-29 Uses of sulphated sugars

Publications (2)

Publication Number Publication Date
CA2020199A1 true CA2020199A1 (en) 1991-12-30
CA2020199C CA2020199C (en) 2002-08-20

Family

ID=4145381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2020199 Expired - Fee Related CA2020199C (en) 1990-06-29 1990-06-29 Uses of sulphated sugars

Country Status (1)

Country Link
CA (1) CA2020199C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
WO2020076501A1 (en) * 2018-10-10 2020-04-16 Hollister Incorporated Stoma powder including skin health ingredients
US11291684B2 (en) 2017-05-17 2022-04-05 Tx Medic Ab Treatment of glaucoma

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2908911A1 (en) * 2012-10-17 2015-08-26 Interalia S.r.l. Compositions comprising a silver salt of sucrose octasulfate and a potassium salt of sucrose octasulfate for protection of mucosal epithelia

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8084441B2 (en) 2003-02-19 2011-12-27 Stellar Pharmaceuticals, Inc. Cystitis treatment with high dose chondroitin sulfate
US8334276B2 (en) 2003-02-19 2012-12-18 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8778908B2 (en) 2003-02-19 2014-07-15 Stellar International Inc. Cystitis treatment with high dose chondroitin sulfate
US11291684B2 (en) 2017-05-17 2022-04-05 Tx Medic Ab Treatment of glaucoma
WO2020076501A1 (en) * 2018-10-10 2020-04-16 Hollister Incorporated Stoma powder including skin health ingredients
CN113038935A (en) * 2018-10-10 2021-06-25 霍利斯特公司 Ostomy powder containing skin healing ingredients
AU2019356464B2 (en) * 2018-10-10 2024-08-22 Hollister Incorporated Stoma powder including skin health ingredients

Also Published As

Publication number Publication date
CA2020199C (en) 2002-08-20

Similar Documents

Publication Publication Date Title
DK151590A (en) USE OF SULPHATED SUGAR
ATE363283T1 (en) TERFENADINE CARBOXYLATE AND THE TREATMENT OF SKIN IRRITATION
CA2000548A1 (en) Conformable bandage and coating material
US5420114A (en) Methods for the treatment of skin disorders
PL330768A1 (en) Perpetration for use in therapy and prophylactics of dermatological diseases
EP0219455A3 (en) Pharmaceutical and cosmetic compositions containing n-acetylcysteine
WO2004100923A1 (en) The composition for external use by percutaneous administration
CA2020199A1 (en) Uses of sulphated sugars
JPH0522689B2 (en)
IT1230157B (en) USE OF WET SUCRALPHATE FOR THE TREATMENT OF DERMA ULCERS AND AS A VEHICLE OF DRUGS WITH TOPICAL ACTIVITY
CN105169457B (en) A kind of cation medical dressing and preparation method thereof
EP0242553A1 (en) Use of allantoin and sulfur in the manufacture of a medicament for the treatment of odontostomatologic diseases
JP2004534076A (en) Use of glycoproteins for wound healing and reepithelialization
JPH039885B2 (en)
CN105056288B (en) Medical hemorrhoid biological hydrogel functional dressings and preparation method thereof
FR2757391B1 (en) USE OF AN EXTRACT FROM THE TERMINALIA PLANT, IN THE COSMETIC AND PHARMACEUTICAL AREAS, ESPECIALLY DERMATOLOGICAL
CN105616296A (en) Populus tomentosa itch-stopping skin-protecting paste
US20050191354A1 (en) Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
CA2126704C (en) Dermatological compositions and methods for the treatment of skin therewith
KR20040087006A (en) Seat-type hydrogel pack using water soluble polymer and the manufacturing process thereof
SU1475669A1 (en) Agent for prevention and treatment of frostbites
HODGSON et al. A clinical comparison between triacetoxyanthracene and dithranol pastes in the treatment of chronic psoriasis
US7018661B2 (en) Aluminum-zirconium compound-based treatment for herpes simplex virus lesions
CA2097878A1 (en) Therapeutic agent for neutropenia
WO2000024370A1 (en) Dermatologic gels for the treatment of acne vulgaris and herpes simplex containing methenamine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed